Nutriband Stock (NASDAQ:NTRB)

Revenue Ownership Financials Chart

Previous Close

$8.53

52W Range

$3.72 - $11.78

50D Avg

$7.59

200D Avg

$6.27

Market Cap

$90.01M

Avg Vol (3M)

$93.30K

Beta

1.23

Div Yield

-

NTRB Company Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Oct 01, 2021

Website

NTRB Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Jan 23	Apr 22
UNITED STATES	$525.53K	-
TransdermalPatchesMember	-	$401.99K
ContractServicesMember	-	$75.93K

Fiscal year ends in Jan 25 | Currency in USD

NTRB Financial Summary

	Jan 25	Jan 24	Jan 23
Revenue	$2.14M	$2.09M	$2.08M
Operating Income	$-10.28M	$-4.87M	$-4.15M
Net Income	$-10.48M	$-5.49M	$-4.81M
EBITDA	$-10.28M	$-5.12M	$-4.11M
Basic EPS	$-0.99	$-0.69	$-0.57
Diluted EPS	$-0.99	$-0.69	$-0.57

Fiscal year ends in Jan 25 | Currency in USD

Peer Comparison

Ticker	Company
BFRI	Biofrontera Inc.
MNOV	MediciNova, Inc.
SOPA	Society Pass Incorporated
CLYM	Climb Bio, Inc.
IMMX	Immix Biopharma, Inc.
ISPC	iSpecimen Inc.
KTTA	Pasithea Therapeutics Corp.